Divi's Labs, Laurus Labs, Sai Life Sciences and Glenmark Pharma quoted at their respective record highs in Monday's trade.
Gland Pharma on Friday posted a 58.29 per cent rise in consolidated net profit to Rs 290.75 crore in the September quarter, driven by strong execution across businesses. The company had reported a net profit of Rs 183.68 crore in the year-ago period. The pharmaceutical company's revenue from operations rose to Rs 1,833.58 crore in the quarter under review from Rs 1,486.87 crore a year ago, the company said in a regulatory filing. Total expenses also rose to Rs 1,471.69 crore in the July-September period from Rs 1,287.12 crore a year earlier, it said. The company launched four molecules -- Sugammadex, Erythromycin, Fluorouracil and Atropine sulfate -- in the US this quarter, it said in a release. Gland Pharma Executive Chairman Srinivas Sadu said, "We delivered another quarter of strong growth...driven by strong execution across our businesses. Our CDMO business grew 31 per cent year-on-year, supported by expanding customer engagements, strategic partnerships and a robust opportuni
Hindalco Industries, Honasa Consumer, Siemens, Aster DM Quality Care, Blue Dart Express, Bombay Dyeing & Manufacturing Company are among the companies to report Q2FY27 results.
India's CRDMO sector growth rebounded to 19% YoY in Q1FY27 versus just 9% YoY in the March 2026 quarter, marking the highest growth level since the December 2024 quarter, notes Jefferies.
Gland Pharma Share: The market price of Gland Pharma hit a high of ₹2,989.2 in intra-day deals on Tuesday. The stock bounced back 90 per cent from its 52-week low of ₹1,575 touched on March 16, 2026.
In the past six months, the stock price of Neuland Labs outperformed the market by surging 68 per cent, as compared to 6 per cent decline in the BSE Sensex.
The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.
Sentiment was further buoyed by bullish brokerage commentary, with Elara Capital and Motilal Oswal Financial Services retaining Buy calls on Gland Pharma, citing strong earnings
Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.
Stocks to Watch today, January 8, 2026: From Tata Steel to Cipla, here is a list of stocks that will be on investors' radar
Stocks to Watch today, November 4, 2025: From Bharti Airtel, Hero MotoCorp, Titan Company, and Power Grid, here is a list of stocks that will be in focus today
The consolidated net profit rose to 1.84 billion rupees (nearly $21 million) for the quarter ended September 30 from 1.64 billion rupees a year earlier
Jefferies is optimistic on India's CRDMO sector, given its evolution from quasi-chemical firms into strategic partners for innovators; check more details
The pharma company's profit after tax (PAT) for the quarter ended June 30, 2025, stood at ₹215 crore, up 50 per cent from ₹143 crore reported in the corresponding quarter of the previous fiscal year.
Sequentially, the company's net profit rose by 15 per cent, and revenue increased by 6 per cent
The daily RSI, a key momentum indicator, shows that these 4 pharma stocks namely - Gland Pharma, Glenmark, Biocon and Laurus Labs are trading in the overbought territory; here's what to expect next.
Gland Pharma shares rose 2 per cent after it received a GMP certification from the Danish Medicines Agency for its Telangana plant
Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.
Gland Pharma share price rose 3 per cent logging an intraday high at ₹1,800 per share; here's why
The Nifty Pharma index and select shares such as Biocon, Cipla, Zydus Life and Gland Pharma were trading above the respective 200-DMAs after more than 2 months; show technical charts.